The findings, published in The British Medical Journal, show that GLP-1RA users were 37 per cent more likely to develop alopecia than SGLT-2 inhibitor users — diabetes drugs which target kidneys to remove extra sugar from urine — while they had a 68 per cent higher risk, compared to users of DPP-4 inhibitors.